# A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC

> **NCT07062328** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 39 (estimated)

## Conditions studied

- Biliary Tract Carcinoma

## Interventions

- **DRUG:** Recaticimab and Adebrelimab
- **DRUG:** GP chemotherapy

## Key facts

- **NCT ID:** NCT07062328
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-10
- **Primary completion:** 2026-12-10
- **Final completion:** 2028-04-20
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2025-07-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07062328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07062328, "A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07062328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*